Taysha Gene Therapies(NASDAQ) TSHA

Taysha Gene Therapies makes medicines to fix broken genes. These treatments help people with rare nervous system disorders. The company focuses on diseases that have no current cures.

Fixing Genes in the Brain

• TSHA-102: Lead gene therapy candidate for females with Rett syndrome, a rare neurodevelopmental disorder.
• TSHA-120: Investigational treatment for giant axonal neuropathy, a condition causing progressive nerve damage.
• TSHA-105: Early-stage program targeting a genetic form of infant epilepsy called SLC13A5 Deficiency.
• CNS Pipeline: Collection of development programs for inherited diseases of the central nervous system (CNS).

Building a Pathway to Market

• Signed a commercial supply agreement with Catalent to produce TSHA-102 in a Maryland manufacturing facility.
• Borrowed $50.0 million through a new loan agreement with Trinity Capital in August 2025 to refinance debt.
• Initiated a process performance qualification campaign in April 2026 to validate manufacturing for regulatory approval.
• Paid a $3.0 million regulatory milestone to Abeona Therapeutics in January 2026 for clinical progress.
• Raised $215.6 million in net proceeds from a public stock offering completed in June 2026.

Engineering Precision Delivery

The company uses a specialized delivery tool called an adeno-associated virus 9 (AAV9) capsid to carry healthy DNA into the central nervous system. This approach allows treatments to reach the brain and spinal cord through a single injection to address the root cause of genetic disorders.

Measuring the Financials

• Market capitalization reached $2.1 billion.
• Cash and cash equivalents totaled $455.4 million as of June 30, 2026.
• Net loss was $89.0 million for the six-month period ended June 30, 2026.
• Research and development expenses were $72.4 million for the six-month period ended June 30, 2026.
• Accumulated deficit reached $800.3 million as of June 30, 2026.

Bottom Line

Taysha has transitioned from early research toward preparing a Biologics License Application for its lead therapy candidate for Rett syndrome. The company has secured significant capital and manufacturing partnerships to support its move toward potential commercial operations.